UK Markets open in 5 hrs 26 mins

The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices

Zacks Equity Research

For Immediate Release

Chicago, IL –October 16, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intel INTC, Oracle ORCL, Novo Nordisk NVO, ConocoPhillips COP and Advanced Micro Devices AMD.

Here are highlights from Tuesday’s Analyst Blog:

Top Analyst Reports for Intel, Oracle and Novo Nordisk

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Intel, Oracle and Novo Nordisk. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Intel’s shares have outperformed the Zacks General Semiconductor industry year to date (3.1% vs. -6.4%). The Zacks analyst believes that Intel is benefiting from rising demand witnessed in its higher performance products, both in data center and client domains.

Moreover, synergies from its Mobileye acquisition and growing clout in ADAS market favor the company’s growth prospects. Further, Intel’s strategy of expanding TAM beyond CPU to adjacent product lines like silicon photonics, fabric, network ASICs, and 3D XPoint memory is yielding results.

The launch of its new 10nm-technology-based AI chip, Springhill, holds promise. However, weakness in demand from China and softness in NAND flash pricing trends, expenses pertaining to 10-nanometer (nm) ramp and constrained supply remain major concerns. Moreover, intensifying competition and pricing pressure from AMD remains a headwind.

Shares of Oracle have gained 3.4% in the past six months, compared with the Zacks Computer Software industry’s rise of 8.2%. The Zacks analyst believes that Oracle is benefiting from strong adoption of cloud-based solutions, comprising NetSuite ERP, Fusion ERP and Fusion HCM, among others.

Partnerships with the likes of Accenture and Microsoft are expected to aid Oracle in expanding cloud-based clientele. Moreover, strong demand for the latest autonomous database supported by ML is likely to bolster the top line and provide a competitive edge against Amazon Web Services (AWS) in the Database-as-a-Service market.

Nonetheless, stiff competition in the cloud market from dominant players is anticipated to weigh on profits. Further, lower hardware volumes are expected to hurt the top line, keeping margins under pressure. Additionally, integration risks from buyouts remain a concern. Notably, shares of Oracle have underperformed the industry in the past year.

Novo Nordisk’s shares have gained 9% over the past three months, compared with the Zacks Biotech industry’s rise of 0.4%. The Zacks analyst believes a solid performance from Tresiba, Victoza, Ozempic, Xultophy and Saxenda have driven the company’s sales in the year so far.

Label expansion of Victoza continues to boost performance. Ozempic, the company’s once-weekly GLP-1, continues to gain market share. The FDA recently approved semaglutide in tablet form under the brand name, Rybelsus. The company continues to evaluate the candidate for multiple indications. Shares of the company have outperformed the industry year to date.

However, lower realized prices in the United States, loss of exclusivity for products in hormone replacement therapy and intensifying competition within the diabetes and biopharmaceuticals markets will adversely impact sales, going ahead.

Other noteworthy reports we are featuring today include ConocoPhillips and Advanced Micro Devices.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                   

https://www.zacks.com                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
 
Oracle Corporation (ORCL) : Free Stock Analysis Report
 
Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report
 
ConocoPhillips (COP) : Free Stock Analysis Report
 
Intel Corporation (INTC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research